Abstract:After surgery, patients with medullary thyroid carcinoma (MTC) should be assessed regarding the presence of residual disease, the localization of metastases, and the identification of progressive disease. Postoperatively, patients with MTC are staged to separate those at low risk from those at high risk of recurrence. The TNM staging system is based on tumor size, extra-thyroidal invasion, nodal metastasis, and distant spread of cancer. In addition, the number of lymph-node metastases, the number of compartments involved, and the postoperative calcitonin (CTN) and carcinoembryonic antigen (CEA) levels should be documented. The postoperative normalization of the serum CTN level is associated with a favorable outcome. When patients have basal serum CTN levels less than 150 pg/ml after a thyroidectomy, any persistent or recurrent disease is nearly always confined to lymph nodes in the neck. When the postoperative serum CTN level exceeds 150 pg/ml, patients should be evaluated with imaging procedures, including computed tomography (CT) of the neck and chest, contrast-enhanced magnetic resonance imaging (MRI) and ultrasound (US) of the liver, bone scintigraphy, MRI of the bone, and positron emission tomography (PET)/CT. One can estimate the growth rate of MTC metastases by quantifying increases in tumor size over time from sequential imaging studies analyzed with response evaluation criteria in solid tumors (RECIST), and by determining the tumor marker doubling time from sequential measures of serum CTN or CEA levels over multiple time points. One of the main challenges remains to find effective adjuvant and palliative options for patients with metastatic disease. Patients with persistent or recurrent MTC localized to the neck following thyroidectomy are candidates for neck operations, depending on the tumor extension. Once metastases appear, the clinician must decide which patients require therapy. This requires a balance between the (often) slow rate of tumor progression, which is associated with a good quality of life, and the limited efficacy and potential toxicities of local and systemic therapies. Considering that metastatic MTC is incurable, the management goals are to provide loco-regional disease control, palliate symptoms of hormonal excess, such as diarrhea, palliate symptomatic metastases, like pain or bone fracture, and control metastases that threaten life, such as bronchial obstruction or spinal cord compression. This can be achieved with palliative surgery, external beam radiation therapy (EBRT), or systemic therapy with tyrosine kinase inhibitor (TKI).

Critically evaluated key points on hereditary medullary thyroid carcinoma

RET S409Y Germline Mutation and Associated Medullary Thyroid Carcinoma.

Approach to the Patients with Medullary Thyroid Cancer

Ultrasound characteristics of medullary thyroid carcinoma

The Trends in Early Precision Diagnosis and Treatment Strategies of Multiple Endocrine Neoplasia Type 2

Discussion in the diagnosis and treatment of medullary thyroid cancer

Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma

Hereditary medullary thyroid carcinoma syndromes: experience from western India

Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma

Medullary thyroid carcinoma: a narrative historical review

Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism

Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine

Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives

Prophylactic thyroidectomy for MEN 2-related medullary thyroid carcinoma based on predictive testing for RET proto-oncogene mutation and basal serum calcitonin in China

[Clinical Diagnosis and Treatment of Familial Medullary Thyroid Carcinoma Caused by a P.c618y RET Proto-Oncogene Mutation in a Chinese Pedigree].

An Unusual Case of Medullary Thyroid Carcinoma and A Revision of Current Literature

Pedigree Screening of a Chinese Multiple Endocrine Neoplasia Type 2A Family and Prophylactic Total Thy-Roidectomy

Long-Term Follow-up in Medullary Thyroid Carcinoma

Multiple Endocrine Neoplasia Type 2B Associated Mixed Medullary and Follicular Thyroid Carcinoma in A Chinese Patient with RET M918T Germline Mutation

An audit of medullary thyroid carcinoma from a tertiary care hospital in northwest India

Sporadic and Familial Medullary Thyroid Carcinoma: A Retrospective Single Center Study on Presentation and Outcome